On August 22, 2024 Bectas Therapeutics reported the company was awarded a $2.75M product development seed grant from the Cancer Prevention Research Institute of Texas (CPRIT) (Press release, Bectas Therapeutics, AUG 22, 2024, View Source [SID1234656652]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These funds will support the pre-clinical development of Bectas’ first-in-class precision antibody and patient selection biomarker that together are designed to overcome resistance to existing cancer treatments for over 200,000 patients per year.

Bectas received the top score amongst their cohort of applicants following rigorous diligence review of Bectas science, business and intellectual property, providing independent confirmation of the value we are creating for cancer patients and our investors.